F 11356, a novel 5HT derivative with unique high intrinsic activity at 5HT1B/1D receptors in models relevant to migraine.

被引：0
|
作者：
John, GW [1 ]
Pauwels, PJ [1 ]
Perez, M [1 ]
Halazy, S [1 ]
Le Grand, B [1 ]
Verscheure, Y [1 ]
Valentin, JP [1 ]
Palmier, C [1 ]
Wurch, T [1 ]
Chopin, P [1 ]
Marien, M [1 ]
Colpaert, FC [1 ]
机构：
[1] Ctr Rech Pierre Fabre, F-81106 Castres, France
来源：
CEPHALALGIA | 1999年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [1] F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine
    John, GW
    Pauwels, PJ
    Perez, M
    Halazy, S
    Le Grand, B
    Verscheure, Y
    Valentin, JP
    Palmier, C
    Wurch, T
    Chopin, P
    Marien, M
    Kleven, MS
    Koek, W
    Assie, MB
    Carilla-Durand, E
    Tarayre, JP
    Colpaert, FC
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 290 (01): : 83 - 95
  • [2] F 11356, a new 5HT derivative, with selective, potent and high efficacy agonist properties at 5HT1B/1D receptors.
    Pauwels, PJ
    John, GW
    Palmier, C
    Tardif, S
    Wurch, T
    Perez, M
    Carilla-Durand, E
    Halazy, S
    Colpaert, FC
    CEPHALALGIA, 1999, 19 (04) : 404 - 405
  • [3] In vitro vascular and neuronal actions of F 11356, a novel high efficacy 5HT1B/D receptor agonist, in models relevant to migraine.
    John, GW
    Valentin, JP
    Le Grand, B
    Bonnafous, R
    Panissié, A
    Vié, B
    Perez, M
    Halazy, S
    Pauwels, PJ
    Colpaert, FC
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R523 - R523
  • [4] In vitro vascular and neuronal actions of F 11356, a novel high efficacy 5-HT1B/1D receptor agonist, in models relevant to migraine.
    John, GW
    Le Grand, B
    Pauwels, PJ
    Perez, M
    Halazy, S
    Valentin, JP
    Bonnafous, R
    Panissié, A
    Vié, B
    Colpaert, FC
    CEPHALALGIA, 1999, 19 (04) : 405 - 405
  • [5] In vivo pharmacological actions of F 11356, a novel high efficacy anti-migraine 5HT1B/1D receptor agonist.
    John, GW
    Verscheure, Y
    Bel, L
    Perez, M
    Halazy, S
    Chopin, P
    Marien, M
    Colpaert, FC
    CEPHALALGIA, 1999, 19 (04) : 405 - 405
  • [6] 5HT1B/1D agonists
    Fox, AW
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1281 - 1282
  • [7] Central sites of actions of zolmitriptan and sumatriptan: 5HT(1B), 5HT(1D) and 5HT(1F) receptor distribution
    Pascual, J
    Castro, ME
    Pazos, A
    CEPHALALGIA, 1997, 17 (06) : 711 - 711
  • [8] Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment
    Huang, Pin-Chung
    Yang, Fu-Chi
    Chang, Ching-Mao
    Yang, Chun-Pai
    UPDATE ON EMERGING TREATMENTS FOR MIGRAINE, 2020, 255 : 99 - 121
  • [9] Consistent migraine relief with frovatriptan, a novel 5HT1B/1D agonist.
    Spierings, ELH
    Keywood, C
    CEPHALALGIA, 1999, 19 (04) : 367 - 367
  • [10] 5HT1B/1D agonists:: Reply
    Deleu, D
    Hanssens, Y
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1282 - 1283
12345